Results 41 to 50 of about 2,075,366 (204)

Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients

BMC Cardiovascular Disorders, 2023
Background Transthyretin amyloidosis cardiomyopathy (ATTR-CM) patients are often older and may be at risk for obstructive epicardial coronary artery disease (oeCAD).
Rana Hassan, Robert J. H. Miller, Jonathan G. Howlett, James A. White, Nowell M. Fine   +4 more
doaj   +1 more source

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study

Orphanet Journal of Rare Diseases, 2023
Background Transthyretin cardiac cardiomyopathy (ATTR-CM) is a rare but life-threatening disease. Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are ...
Cheng-Hsuan Tsai, Chi-Chao Chao, Sung-Tsang Hsieh, An-Li Yu, Yuan-Kun (Aden) Wu, Mei-Fang Cheng, Ming-Jen Lee, Chia-Hung Chou, Chia-Tung Shun, Hsueh-Wen Hsueh, Jimmy Jyh-Ming Juang, Ping-Huei Tseng, Mao-Yuan Su, Yen-Hung Lin   +13 more
doaj   +1 more source

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage

ESC Heart Failure, 2020
Aims Cardiac transthyretin amyloidosis (ATTR‐CM) is a progressive and fatal condition. Prognosis can be determined at diagnosis according to the National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage.
Steven Law, Aviva Petrie, Liza Chacko, Oliver C. Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez‐Naharro, Helen J. Lachmann, Carol J. Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore   +14 more
doaj   +1 more source

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. [PDF]

, 2022
AIMS Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid ...
Asatryan, Babken, Bernhard, Benedikt, Dobner, Stephan, Gräni, Christoph, Hunziker, Lukas, Pilgrim, Thomas, Stortecky, Stefan, Windecker, Stephan   +7 more
core   +1 more source

Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an important cause of heart failure in older individuals. Misfolding and deposition of transthyretin or prealbumin protein causes ATTR‐CM in the context of a normal (wild‐type) or variant TTR ...
Frederick L. Ruberg, William S. Blaner, Codruta Chiuzan, Lawreen H. Connors, Andrew J. Einstein, Denise Fine, Stephen Helmke, Damian Kurian, Shivda Pandey, Farbod Raiszadeh, Carlos Rodriguez, Natalia Sabogal, Sergio Teruya, Morgan Winburn, Wendy K. Chung, Elizabeth Cohn, Edward J. Miller, Jeffery W. Kelly, Mathew S. Maurer   +18 more
doaj   +1 more source

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis [PDF]

, 2022
Aims: transthyretin amyloid cardiomyopathy (ATTR-CM) is predominantly diagnosed in men. The few available studies suggest affected women have a more favourable cardiac phenotype.
Adam Ioannou, Aldostefano Porcari, Ambra Masi, Ana Martinez-Naharro, Ashutosh Wechalekar, Aviva Petrie, Carol Whelan, Charlotte Manisty, Daniel Knight, Dorota Rowczenio, Francesco Bandera, Gianfranco Sinagra, Helen Lachmann, James Brown, James Moon, Janet A. Gilbertson, Julian D. Gillmore, Kiara Patel, Liza Chacko, Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Rishi K. Patel, Tushar Kotecha, Yousuf Razvi   +24 more
core   +5 more sources

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries

ESC Heart Failure, 2022
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan.
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H. Rozenbaum, Anne Mette Strand, Merja Väkeväinen, Johanna Kuusisto, Einar Gude, J. Gustav Smith, Finn Gustafsson   +10 more
doaj   +1 more source

Progress in RNA-targeting and Gene Editing Therapies for Transthyretin Amyloidosis Cardiomyopathy

罕见病研究, 2023
Transthyretin(TTR) protein is a tetramer protein, synthesized mainly by the liver. TTR can be misfolded and deposited as amyloid fibrilae and deposited in the myocardial interstroma leading to transthyroxin amyloidosis cardiomyopathy (ATTR-CM).
NIU Ziran, HU Yang, LIU Qingyang, MA Yuanyuan, LIU Jianing, LIU Xin, ZHANG Bo   +6 more
doaj   +1 more source

Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain [PDF]

, 2021
Objective: to estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS ...
Formiga Pérez, Francesc, Garcia Pavia, Pablo, López-Ibáñez de Aldecoa, Alejandra, Martín Sánchez, Francisco Javier, Navarro-Ruiz, Andrés, Peral, Carmen, Rubio-Rodríguez, Darío, Rubio-Terrés, Carlos, Tarilonte, Patricia   +8 more
core   +1 more source

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy [PDF]

Transthyretin amyloid cardiomyopathy (ATTR-CM) has been traditionally considered a rare and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart failure (HF) and mortality worldwide with effective pharmacological ...
Fontana, Marianna, Gillmore, Julian D, Hawkins, Philip N, Porcari, Aldostefano, Sinagra, Gianfranco   +4 more
core   +4 more sources